Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Perflubutane - Daiichi Sankyo/GE Healthcare

Next Previous
X
Search
Drug Profile

Perflubutane - Daiichi Sankyo/GE Healthcare

Alternative Names: DD-723; DD-723-B; NC-100100; NUS; Sonazoid

Latest Information Update: 27 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GE Healthcare
  • Developer Daiichi Sankyo Company; GE Healthcare; Yonsei University Health System
  • Class Contrast media; Fluorocarbons; Small molecules
  • Mechanism of Action Ultrasonography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Liver cancer
  • Phase II Renal transplant rejection
  • Discontinued Liver disorders; Prostate cancer; Vascular disorders

Most Recent Events

  • 27 Nov 2024 Discontinued - Phase-III for Liver cancer (Diagnosis) in South Korea (IV)
  • 27 Nov 2024 Discontinued - Phase-III for Liver disorders (Diagnosis) in China, South Korea, Taiwan (IV)
  • 01 Feb 2023 GE Healthcare completes a phase I trial in Renal transplant rejection (Diagnosis) in USA (IV) (NCT02733029)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top